Purpose: Chemotherapy-induced amenorrhea (CIA) by newer taxane-containing regimens was evaluated in early breast cancer (EBC) patients. Methods: A prospective cohort of 122 premenopausal EBC patients participated in a phase III trial of preoperative docetaxel/capecitabine (TX) versus doxorubicin/cyclophosphamide (AC); 34 patients received adjuvant AC followed by paclitaxel (T) and 129 patients received 5-fluorouracil/doxorubicin/cyclophosphamide (FAC). Results: The CIA rate was 90.2% with TX/AC, 73.5% with AC followed by T, and 72.1% with FAC at 1 year (P = 0.002), and 66.7%, 73.3%, and 58.9%, respectively, at 3 years (P = 0.268). At one year, age (P < 0.001) and taxane use (P = 0.002), and after two years, age and tamoxifen use were significant factors for CIA in multivariate analysis. Serum estradiol and follicle-stimulating hormone levels were significantly correlated with menstrual status, age, and tamoxifen use. Conclusion: Taxanes resulted in higher CIA rates in the first year, but age and tamoxifen use were significant factors for persistent CIA.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 365(9472):1687–1717. doi:10.1016/S0140-6736(05) 66544-0
Bines J, Oleske DM, Cobleigh MA (1996) Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 14(5):1718–1729
Shapiro CL, Recht A (2001) Side effects of adjuvant treatment of breast cancer. N Engl J Med 344(26):1997–2008. doi:10.1056/NEJM200106283442607
Walshe JM, Denduluri N, Swain SM (2006) Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol 24(36):5769–5779. doi:10.1200/JCO.2006.07.2793
Minton SE, Munster PN (2002) Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control 9(6):466–472
Knobf MT (2006) The influence of endocrine effects of adjuvant therapy on quality of life outcomes in younger breast cancer survivors. Oncologist 11(2):96–110. doi:10.1634/theoncologist.11-2-96
National Cancer Center Central Cancer Registry, Korea (2002) Cancer statics in Korea
Pritchard KI (2007) Risk of chemotherapy induced menopause: more detailed data will lead to improved quality of life. Eur J Cancer 43(11):1644–1645. doi:10.1016/j.ejca.2007.05.027
Goldhirsch A, Gelber RD, Castiglione M (1990) The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. The International Breast Cancer Study Group. Ann Oncol 1(3):183–188
Levine MN, Pritchard KI, Bramwell VH et al (2005) Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol 23(22):5166–5170. doi:10.1200/JCO.2005.09.423
Fornier MN, Modi S, Panageas KS, Norton L, Hudis C (2005) Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer 104(8):1575–1579. doi:10.1002/cncr.21385
Davis AL, Klitus M, Mintzer DM (2005) Chemotherapy-induced amenorrhea from adjuvant breast cancer treatment: the effect of the addition of taxanes. Clin Breast Cancer 6(5):421–424
Tham YL, Sexton K, Weiss H, Elledge R, Friedman LC, Kramer R (2007) The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol 30(2):126–132. doi:10.1097/01.coc.0000251398.57630.4f
Martin M, Pienkowski T, Mackey J et al (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352(22):2302–2313. doi:10.1056/NEJMoa043681
Lee KS, Ro J, Nam BH, Lee ES, Kwon Y, Kwon HS, Chung KW, Kang HS, Kim EA, Kim SW, Shin KH, Kim SK (2007) A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer. Breast Cancer Res Treat. doi:10.1007/s105490079672
Petrek JA, Naughton MJ, Case LD, Paskett ED, Naftalis EZ, Singletary SE et al (2006) Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 24(7):1045–1051. doi:10.1200/JCO.2005.03.3969
Kil WJ, Ahn SD, Shin SS, Lee SW, Choi EK, Kim JH et al (2006) Treatment-induced menstrual changes in very young (<35 years old) breast cancer patients. Breast Cancer Res Treat 96(3):245–250. doi:10.1007/s10549-005-9059-x
Jones SE, Savin MA, Holmes FA, O’Shaughnessy JA, Blum JL, Vukelja S et al (2006) Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24(34):5381–5387. doi:10.1200/JCO.2006.06.5391
Brincker H, Rose C, Rank F, Mouridsen HT et al (1987) Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer. J Clin Oncol 5(11):1771–1778
Reyno LM, Levine MN, Skingley P, Arnold A, Abu Zahra H (1992) Chemotherapy induced amenorrhoea in a randomised trial of adjuvant chemotherapy duration in breast cancer. Eur J Cancer 29A(1):21–23
Colleoni M, Gelber S, Goldhirsch A et al (2006) Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J Clin Oncol 24(9):1332–1341. doi:10.1200/JCO.2005.03.0783
Burger HG (1996) The endocrinology of the menopause. Maturitas 23(2):129–136. doi:10.1016/0378-5122(95) 00969-8
Bromberger JT, Assmann SF, Avis NE, Schocken M, Kravitz HM, Cordal A (2003) Persistent mood symptoms in a multiethnic community cohort of pre- and perimenopausal women. Am J Epidemiol 158(4):347–356. doi:10.1093/aje/kwg155
Samaan NA, deAsis DN Jr, Buzdar AU, Blumenschein GR (1978) Pituitary-ovarian function in breast cancer patients on adjuvant chemoimmunotherapy. Cancer 41(6):2084–2087. doi:10.1002/1097-0142(197806)41:6≤2084::AID-CNCR2820410603≥3.0.CO;2-Y
Mehta RR, Beattie CW, Das Gupta TK (1992) Endocrine profile in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat 20(2):125–132. doi:10.1007/BF01834642
Gracia CR, Sammel MD, Freeman EW, Lin H, Langan E, Kapoor S et al (2005) Defining menopause status: creation of a new definition to identify the early changes of the menopausal transition. Menopause 12(2):128–135. doi:10.1097/00042192-200512020-00005
Parulekar WR, Day AG, Ottaway JA, Shepherd LE, Trudeau ME, Bramwell V et al, National Cancer Institute of Canada Clinical Trials Group (2005) National Cancer Institute of Canada Clinical Trials Group. Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study-NCIC CTG MA.5. J Clin Oncol 23(25):6002–6008. doi:10.1200/JCO.2005.07.096
This study was supported by NCC Grant No. NCS-07-103.
About this article
Cite this article
Han, H., Ro, J., Lee, K.S. et al. Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer. Breast Cancer Res Treat 115, 335 (2009). https://doi.org/10.1007/s10549-008-0071-9
- Adjuvant chemotherapy
- Breast cancer